Market Overview:
The global Enterprise Resource Planning (ERP) Market is estimated to be valued at USD 44.47 billion in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period from 2023 to 2030, according to a new report published by Coherent Market Insights. ERP is a business management software that enables organizations to integrate and manage various core processes, such as manufacturing, procurement, human resources, finance, and sales, in a centralized system. This streamlined approach enhances overall productivity, efficiency, and decision-making capabilities of enterprises. The increasing need for real-time data analysis, improved operational efficiency, and cost reduction are driving the adoption of ERP software across various industries.
Market Key Trends:
One of the key trends in the ERP market is the growing adoption of cloud-based ERP solutions. Cloud-based ERP offers several advantages over traditional on-premise solutions, including lower upfront costs, scalability, flexibility, and ease of implementation. Cloud-based ERP systems also enable remote access to data, allowing employees to work from anywhere, which is particularly beneficial in today's remote work environment. Additionally, cloud-based ERP solutions provide automatic software updates, data security, and improved collaboration and communication within the organization. The increasing demand for cost-effective and efficient business solutions, along with the need for greater agility and scalability, is expected to drive the growth of cloud-based ERP solutions in the coming years.
Segment Analysis:
The global enterprise resource planning (ERP) market can be segmented based on deployment type, organization size, industry, and region. Based on deployment type, the cloud-based ERP segment dominates the market. Cloud-based ERP systems offer several advantages such as scalability, flexibility, cost-effectiveness, and accessibility from anywhere. These factors have led to the increased adoption of cloud-based ERP solutions by organizations across various industries. Furthermore, the cloud-based ERP segment is expected to witness significant growth in the forecast period due to the rising demand for remote access and real-time data analysis.
In terms of organization size, large enterprises dominate the ERP market. Large enterprises typically have complex operations and require robust ERP systems to streamline their processes, manage resources, and improve operational efficiency. Small and medium-sized enterprises (SMEs) are also increasingly adopting ERP systems, but the market penetration is relatively lower compared to large enterprises. However, with the availability of cloud-based ERP solutions, SMEs are expected to contribute significantly to the market growth in the coming years.
Based on the industry, the manufacturing sector dominates the ERP market. Manufacturing companies rely heavily on ERP systems to manage their production processes, inventory, supply chain, and other critical operations. ERP solutions help manufacturers optimize their resources, reduce costs, and improve productivity. Other industries such as retail, healthcare, BFSI, and IT & Telecom are also adopting ERP systems to enhance their operational efficiency.
Key Takeaways:
The Global Enterprise Resource Planning (ERP) Market Demand is poised to witness high growth, exhibiting a CAGR of 6.2% over the forecast period (2023 to 2030). This growth can be attributed to several factors. Firstly, the increasing adoption of cloud-based ERP systems, driven by the advantages of scalability, flexibility, and cost-effectiveness. Organizations are increasingly realizing the benefits of cloud-based ERP solutions in terms of remote access, real-time data analysis, and reduced upfront investment.
From a regional perspective, North America is expected to be the fastest-growing and dominating region in the ERP market. The region has a strong presence of key ERP solution providers and early technology adopters, contributing to the market growth. Furthermore, the increasing adoption of cloud-based ERP solutions and the presence of several manufacturing and service sector organizations fuel the market growth in North America.
Key players operating in the ERP market include Oracle Corporation, IBM Corporation, Microsoft Corporation, SAP, Infor, Sage, Netsuite Inc., SYSPRO, Epicor Software Company, and Daffodil Software Ltd. These key players offer a wide range of ERP solutions catering to various industries and organization sizes. They focus on strategic partnerships, product innovation, and expanding their customer base to maintain their competitive position in the market.
With the advent of technological innovations and advancements, the ERP software market is expanding its dimensions all across the globe.
The market size of ERP in North America is worth more than $10 billion Read more....
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
